Cosmetics Europe multi-laboratory pre-validation of the EpiOcular? reconstituted human tissue test method for the prediction of eye irritation

详细信息    查看全文

• 作者：U. Pfannenbecker^a ; ^{Uwe.Pfannenbecker@Beiersdorf.com} ; S. Bessou-Touya^b ; C. Faller^c ; ¹ ; J. Harbell^d ; T. Jacob^e ; H. Raabe^f ; M. Tailhardat^g ; N. Alé ; pé ; e^h ; A. De Smedtⁱ ; B. De Wever^j ; P. Jones^k ; Y. Kaluzhny^l ; B. Le Varlet^m ; P. McNameeⁿ ; M. Marrec-Fairley^o ; ² ; F. Van Goethemⁱ
• 关键词：ANOVA ; analysis of variance ; BCOP ; bovine corneal opacity and permeability test ; BLV ; between laboratory variability ; CE ; cosmetics Europe the personal care association ; ECVAM ; European centre for the validation of alternative methods ; EIT ; Eye Irritation
• 刊名：Toxicology in Vitro
• 出版年：2013
• 出版时间：March, 2013
• 年：2013
• 卷：27
• 期：2
• 页码：619-626
• 全文大小：826 K

文摘

Cosmetics Europe, The Personal Care Association (known as Colipa before 2012), conducted a program of technology transfer and within/between laboratory reproducibility of MatTek Corporation¡¯s EpiOcular? Eye Irritation Test (EIT) as one of the two human reconstructed tissue test methods. This EIT EpiOcular? used a single exposure period for each chemical and a prediction model based on a cut-off in relative survival [?60 %  = irritant (I) (GHS categories 2 and 1); >60 %  = no classification (NC)]. Test substance single exposure time was 30 min with a 2-h post-exposure incubation for liquids and 90 min with an 18-h post-exposure incubation for solids. Tissue viability was determined by tetrazolium dye (MTT) reduction. Combinations of 20 coded chemicals were tested in 7 laboratories. Standardized laboratory documentation was used by all laboratories. Twenty liquids (11 NC/9 I) plus 5 solids (3 NC/2 I) were selected so that both exposure regimens could be assessed. Concurrent positive (methyl acetate) and negative (water) controls were tested in each trial. In all, 298 independent trials were performed and demonstrated 99.7 % agreement in prediction (NC/I) across the laboratories. Coefficients of variation for the % survival for tissues from each treatment group across laboratories were generally low. This protocol has entered in 2010 the experimental phase of a formal ECVAM validation program.